» Articles » PMID: 39513598

Hyperthermia Reduces Cancer Cell Invasion and Combats Chemoresistance and Immune Evasion in Human Bladder Cancer

Overview
Journal Int J Oncol
Specialty Oncology
Date 2024 Nov 8
PMID 39513598
Authors
Affiliations
Soon will be listed here.
Abstract

Bladder cancer (BC) is a common malignancy and its most prevalent type is urothelial carcinoma, which accounts for ~90% of all cases of BC. The current treatment options for BC are limited, which necessitates the development of alternative treatment strategies. Hyperthermia (HT), as an adjuvant cancer therapy, is known to improve the efficacy of chemotherapy or radiotherapy. The present study aimed to investigate the anti‑tumor effects of HT on cell survival, invasiveness, chemoresistance and immune evasion in human BC cell lines (5637, T24 and UMUC3). Calcein AM staining was performed to analyze the cytotoxicity of natural killer (NK) cells against human BC cells following HT treatment. Cell migration and invasion affected by HT were analyzed using Transwell migration and invasion assays. It was found that HT inhibited the proliferation of BC cells by downregulating the phosphorylation of protein kinase B. Moreover, HT effectively enhanced the sensitivity of BC cells to the chemotherapy drug cisplatin (DDP) and reduced the chemoresistance of DDP‑resistant cells by downregulating the expression of cadherin‑11. It was further demonstrated that HT inhibited the migration and invasion of BC cells and enhanced the cytotoxic effects of NK cells. In summary, the antineoplastic effects of HT were mediated through three main mechanisms: Enhancement of the chemosensitivity of BC cells and mitigation of DDP‑induced chemoresistance, suppression of the invasive potential of BC cells and reinforcement of the anticancer response of NK cells. Thus, HT appears to be a promising adjunctive therapy for human BC.

References
1.
Chang A, Chen P, Lin Y, Su C, Liu J, Lin T . Osteoblast-secreted WISP-1 promotes adherence of prostate cancer cells to bone via the VCAM-1/integrin α4β1 system. Cancer Lett. 2018; 426:47-56. DOI: 10.1016/j.canlet.2018.03.050. View

2.
Tsang Y, Huang C, Yang K, Chi M, Chiang H, Wang Y . Improving immunological tumor microenvironment using electro-hyperthermia followed by dendritic cell immunotherapy. BMC Cancer. 2015; 15:708. PMC: 4608323. DOI: 10.1186/s12885-015-1690-2. View

3.
Colombo R, Salonia A, Leib Z, Pavone-Macaluso M, Engelstein D . Long-term outcomes of a randomized controlled trial comparing thermochemotherapy with mitomycin-C alone as adjuvant treatment for non-muscle-invasive bladder cancer (NMIBC). BJU Int. 2010; 107(6):912-8. DOI: 10.1111/j.1464-410X.2010.09654.x. View

4.
Vancsik T, Mathe D, Horvath I, Varallyaly A, Benedek A, Bergmann R . Modulated Electro-Hyperthermia Facilitates NK-Cell Infiltration and Growth Arrest of Human A2058 Melanoma in a Xenograft Model. Front Oncol. 2021; 11:590764. PMC: 7959784. DOI: 10.3389/fonc.2021.590764. View

5.
van der Heijden A, Verhaegh G, Jansen C, Schalken J, Witjes J . Effect of hyperthermia on the cytotoxicity of 4 chemotherapeutic agents currently used for the treatment of transitional cell carcinoma of the bladder: an in vitro study. J Urol. 2005; 173(4):1375-80. DOI: 10.1097/01.ju.0000146274.85012.e1. View